Jefferies keeps Buy rating for UroGen Pharma stock education? no

Published on 10/08/2026 at 16:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 72.5 million in second quarter, up from USD 24.2 million. UroGen Pharma stock costs EUR 31.27 after EUR 36.44, down 14.19 percent.

Key points in brief

Jefferies reiterated a Buy rating and a USD 56.00 target for UroGen Pharma on September 10, 2026.
Second-quarter revenue reached USD 72.5 million, versus USD 24.2 million a year earlier.
UroGen Pharma stock was EUR 31.27 at Lang & Schwarz on October 8, 2026, down 14.19 percent from EUR 36.44.
UroGen's Nasdaq listing trades in USD, with a USD 15.86 to USD 50.81 52-week range.
The next earnings date is November 5, 2026.

URGN, IL0011407140, Illustration mit AI erstellt.

Jefferies reiterated a Buy rating and a USD 56.00 price target for UroGen Pharma stock on September 10, 2026, according to Investing.com. UroGen Pharma (ISIN IL0011407140) was trading at EUR 31.27 at Lang & Schwarz on October 8, 2026 at 4:40 p.m. CEST, down 14.19 percent from the prior close of EUR 36.44.

Revenue scales with ZUSDURI

Yahoo Finance reported that total revenue reached USD 72.5 million in the second quarter of 2026, compared with USD 24.2 million in the second quarter of 2025. The same call showed a net loss of USD 14.4 million, down from USD 49.9 million in the year-earlier quarter.

ZUSDURI generated USD 50.4 million in net product revenue in the second quarter, while JELMYTO contributed USD 22.0 million. Management also maintained 2026 JELMYTO revenue guidance of USD 97 million to USD 101 million, according to Yahoo Finance.

Three milestones shape the pipeline

On August 17, 2026, UroGen submitted a New Drug Application for UGN-103. The filing followed data showing a 77.80 percent complete response rate, as reported by MedFind.

On August 20, 2026, UroGen agreed to a strategic collaboration with IntraGel that provides a research license and options covering up to three oncology products, according to Makkler. On September 10, 2026, Jefferies kept its Buy rating and USD 56.00 target after data from a competing bladder-cancer candidate, according to Investing.com.

What does the launch mean?

The second-quarter revenue comparison shows the commercial launch is already changing UroGen's scale, while the USD 14.4 million loss shows that profitability has not yet followed revenue growth. The company also reported 1,444 activated accounts and 452 unique prescribers as of June 30, 2026, according to Yahoo Finance.

Next date and market context

UroGen's next earnings date is November 5, 2026, according to ToAlpha. The company develops and commercializes treatments for urothelial and specialty cancers through its RTGel sustained-release platform, including ZUSDURI and JELMYTO, according to UroGen Pharma.

On Nasdaq, UroGen Pharma was last at USD 34.88 on October 8, 2026 at 10:50 a.m. ET. Its market capitalization was USD 1.7 billion, and its 52-week range was USD 15.86 to USD 50.81 on the same date. The further course of trading is shown by the continuously updated real-time quote of UroGen Pharma stock.